Infiniplex develops a liquid biopsy technology that utilizes quantitative Real-Time PCR to detect genetic tumor mutations in cell-free DNA from routine blood tests. This approach enables early cancer detection and monitoring by identifying multiple mutations across various cancer types in a single, non-invasive test.
Funding
Funding not disclosed
TVFounders
Product
Problem
Current methods for cancer detection and monitoring often involve invasive procedures or imaging techniques, which can be costly, time-consuming, and expose patients to radiation. The need for frequent monitoring of cancer treatment efficacy also presents a challenge, as repeated biopsies are not practical or desirable for patients.
Solution
Infiniplex has developed a liquid biopsy technology that uses quantitative Real-Time PCR (qPCR) to detect genetic tumor mutations from cell-free DNA (cfDNA) found in routine blood samples. This non-invasive approach enables early cancer detection and continuous monitoring of treatment response by identifying multiple mutations across various cancer types in a single test. Their technology leverages proprietary AI-designed primers to selectively amplify mutated DNA fragments, increasing the efficiency and specificity of mutation detection in cfDNA. By using a multiplexing method, the Infiniplex test can identify dozens of mutations in a single assay, providing a comprehensive view of the patient's cancer profile. The test aims to make cancer screenings more accessible, affordable, and personalized, facilitating preemptive, preventive, and follow-up cancer monitoring.
Target Audience
The primary target audience includes oncologists, hospitals, and diagnostic laboratories seeking to improve cancer detection and monitoring through non-invasive, accessible, and personalized testing.
Features
- Utilizes cell-free DNA (cfDNA) from routine blood samples for non-invasive cancer detection and monitoring.
- Employs quantitative Real-Time PCR (qPCR) technology for accurate mutation detection.
- Detects multiple mutations across various cancer types in a single test using a multiplexing method.
- Proprietary AI-based system designs novel primers that selectively amplify mutated DNA fragments.
- Provides a comprehensive cancer profile by identifying dozens of mutations in a single assay.